| Literature DB >> 27801345 |
X D Wei1, H Ai, R H Mi, L Chen, F F Yuan, Q M Hao, Q S Yin, P Wang, Y P Song.
Abstract
In 12 patients with relapsed or refractory acute myelogenous leukemia (AML), the efficacy and safety of a novel regimen, namely thalidomide combined with interferon and interleukin 2 (IL-2), were initially explored.All the patients have received the triple-drug regimen for at least one cycle.Three patients achieved incomplete remission (CRi), 3 patients with partial remission.The overall response rate (ORR) was 50%.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27801345 DOI： 10.3760/cma.j.issn.0578-1426.2016.11.013
Source DB: PubMed Journal: Zhonghua Nei Ke Za Zhi ISSN： 0578-1426